New Data for HER2 and HER3 Directed DXd ADCs at SABCS includes longer follow-up research data for ENHERTU® based on DESTINY-Breast01, including updated duration of response, progression-free survival, an 18-month landmark analysis of overall survival and longer-term safety profile to be highlighted

New data from expansion cohorts of phase 1/2 study of patritumab deruxtecan in patients with HR positive, HER2 negative metastatic breast cancer with varying levels of HER3 expression or patients with HER3 high triple negative breast cancer to be presented for first time

New research data for ENHERTU® (fam-trastuzumab deruxtecan-nxki) and patritumab deruxtecan (U3-1402; HER3-DXd), two DXd antibody drug conjugates (ADC), will be presented at the 2020 San Antonio Breast Cancer Symposium (#SABCS20) virtual conference to be held December 8-11, 2020.

Updated results from the pivotal phase 2 DESTINY-Breast01 trial of ENHERTU, a HER2 directed ADC, reporting updated duration of response, progression-free survival, an 18-month landmark analysis of overall survival and longer-term safety seen in previously treated patients with HER2 positive metastatic breast cancer will be presented as a Spotlight Poster Discussion. A first look at new data from the phase 1/2 trial of patritumab deruxtecan, a HER3 directed ADC, reporting on four expansion cohorts of patients with hormone receptor (HR) positive, HER2 negative metastatic breast cancer with varying levels of HER3 expression and triple negative breast cancer with higher levels of HER3 expression will also be presented.

Additional data to be presented at SABCS includes the initial safety and efficacy results of a phase 1 trial combining ENHERTU with nivolumab in a cohort of patients with HER2 expressing metastatic breast cancer. Trial-in-progress updates from four additional DESTINY-Breast studies will also be presented, including a summary of the first study of ENHERTU in patients with early breast cancer in a head-to-head comparison with ado-trastuzumab emtansine (T-DM1).

Download PDF for additional information and timing of the presentations on Fam-trastuzumab deruxtecan-nxki and Patritumab Deruxtecan (U3-1402; HER3-DXd)

 

 

Additional Clinical trials
Trastuzumab deruxtecan (Breast cancer)

  • A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) – NCT04622319
  • Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer – NCT04553770
  • Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06) – NCT04494425
  • A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04) – NCT04539938
  • DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease (DEBBRAH) – NCT04420598
  • A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations (DPT01) – NCT04639219
  • Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer – NCT04294628
  • A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer (DB-07) – NCT04538742
  • DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] – NCT03529110
  • Trastuzumab Deruxtecan (DS-8201a) Versus Investigator’s Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04] – NCT03734029
  • DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02] – NCT03523585
  • DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer – NCT04042701
  • A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (DB-08) – NCT04556773
  • A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (BEGONIA) – NCT03742102
  • A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) – NCT03248492

Patritumab deruxtecan (Breast cancer)

A Window-of-opportunity Study of U3-1402, a HER3-targeting Antibody-drug Conjugate in Operable Breast Cancer According to ERBB3 Expression (TOT-HER3) – NCT04610528

Author